ArticleJournal of the American Academy of Dermatology2020
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.The Journal of allergy and clinical immunology · 2021Pooled it
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.Journal of the American Academy of Dermatology · 2020Guideline
- Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.Acta dermato-venereologica · 2023Trial
- Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.The Journal of allergy and clinical immunology · 2021Trial
- Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study.Dermatology and therapy · 2025Article
- Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters.Vaccines · 2024Review
- The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.Current dermatology reports · 2023Review
- Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials.Therapeutic advances in chronic disease · 2023Article
- SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.Dermatologic therapy · 2022Review
- Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence.The Journal of investigative dermatology · 2022Article
- Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.Biomedicines · 2022Review
- Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics.Frontiers in medicine · 2022Article
- Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis.Frontiers in immunology · 2022Article
- The Use of Biologics During the COVID-19 Pandemic.Dermatologic clinics · 2021Review
- Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: a clinical review.Dermatology online journal · 2021Review
- Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.The Journal of clinical and aesthetic dermatology · 2021Review
- COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.Clinical and experimental dermatology · 2021Article
- Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.American journal of clinical dermatology · 2021Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.